Safety and clinical activity of JNJ-78306358, a human leukocyte antigen-G (HLA-G) x CD3 bispecific antibody, for the treatment of advanced stage solid tumors

Background JNJ-78306358 is a bispecific antibody that redirects T cells to kill human leukocyte antigen-G (HLA-G)-expressing tumor cells. This dose escalation study evaluated the safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of JNJ-78306358 in patients with advanced...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer Immunology, Immunotherapy : CII Jg. 73; H. 10; S. 205
Hauptverfasser:	Geva, Ravit, Vieito, Maria, Ramon, Jorge, Perets, Ruth, Pedregal, Manuel, Corral, Elena, Doger, Bernard, Calvo, Emiliano, Bardina, Jorge, Garralda, Elena, Brown, Regina J., Greger, James G., Wu, Shujian, Steinbach, Douglas, Yao, Tsun-Wen Sheena, Cao, Yu, Lauring, Josh, Chaudhary, Ruchi, Patel, Jaymala, Patel, Bharvin, Moreno, Victor
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Berlin/Heidelberg Springer Berlin Heidelberg 06.08.2024 Springer Nature B.V
Schlagworte:	Adult Aged Aged, 80 and over Antibodies, Bispecific - administration & dosage Antibodies, Bispecific - adverse effects Antibodies, Bispecific - pharmacology Antibodies, Bispecific - therapeutic use Antigens Antitumor activity Bispecific antibodies Cancer Research CD3 antigen CD3 Complex - immunology Cell activation Colorectal cancer Colorectal carcinoma Cytokines Dosage Female Histocompatibility antigen HLA HLA-G Antigens Humans Immunohistochemistry Immunology Kidney cancer Leukocytes Lymphocytes T Male Medicine Medicine & Public Health Metastases Middle Aged Monoclonal antibodies NCT NCT04991740 Neoplasm Staging Neoplasms - drug therapy Neoplasms - immunology Oncology Ovarian cancer Ovarian carcinoma Patients Pharmacodynamics Pharmacokinetics Pneumonitis Renal cell carcinoma Solid tumors Tumor cells Tumors Dose escalation study JNJ-78306358 Cytokine release syndrome Phase 1 Solid tumors Human leukocyte antigen-G
ISSN:	1432-0851, 0340-7004, 1432-0851
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!